Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA.
Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, 40536, USA.
Psychopharmacology (Berl). 2020 Jul;237(7):2075-2087. doi: 10.1007/s00213-020-05519-7. Epub 2020 May 6.
Kappa-opioid receptor (KOR) agonists are antinociceptive but have side effects that limit their therapeutic utility. New KOR agonists have been developed that are fully efficacious at the KOR but may produce fewer or reduced side effects that are typical of KOR agonists.
We determined behavioral profiles for typical and atypical KOR agonists purported to differ in intracellular-signaling profiles as well as a mu-opioid receptor (MOR) agonist, oxycodone, using a behavioral scoring system based on Novak et al. (Am J Primatol 28:124-138, 1992, Am J Primatol 46:213-227, 1998) and modified to quantify drug-induced effects (e.g., Duke et al. J Pharmacol Exp Ther 366:145-157, 2018).
Six adult male rhesus monkeys were administered a range of doses of the typical KOR agonists, U50-488H (0.0032-0.1 mg/kg) and salvinorin A (0.00032-0.01 mg/kg); the atypical KOR agonists, nalfurafine (0.0001-0.001 mg/kg) and triazole 1.1 (0.01-0.32 mg/kg); the MOR agonist, oxycodone (0.0032-0.32 mg/kg); and as controls, cocaine (0.032-0.32 mg/kg) and ketamine (0.32-10 mg/kg). For time-course determinations, the largest dose of each KOR agonist or MOR agonist was administered across timepoints (10-320 min). In mixture conditions, oxycodone (0.1 mg/kg) was followed by KOR-agonist administration.
Typical KOR agonists produced sedative-like and motor-impairing effects. Nalfurafine was similar to typical KOR agonists on most outcomes, and triazole 1.1 produced no effects on its own except for reducing scratch during time-course determinations. In the mixture, all KOR agonists reduced oxycodone-induced scratching, U50-488H and nalfurafine reduced species-typical activity, and U50-488H increased rest/sleep posture.
Atypical "biased" KOR agonists produce side-effect profiles that are relatively benign (triazole 1.1) or reduced (nalfurafine) compared to typical KOR agonists.
κ-阿片受体(KOR)激动剂具有抗伤害作用,但副作用限制了其治疗用途。已经开发出新型 KOR 激动剂,它们在 KOR 上完全有效,但可能产生较少或较少的副作用,这些副作用是典型的 KOR 激动剂。
我们使用基于 Novak 等人的行为评分系统(Am J Primatol 28:124-138,1992;Am J Primatol 46:213-227,1998)以及修改后的方法来确定典型和非典型 KOR 激动剂的行为特征,这些激动剂据称在细胞内信号转导特征上有所不同,以及μ-阿片受体(MOR)激动剂奥昔康定,以定量药物诱导的效应(例如,Duke 等人,J Pharmacol Exp Ther 366:145-157,2018)。
6 只成年雄性恒河猴给予一系列剂量的典型 KOR 激动剂 U50-488H(0.0032-0.1mg/kg)和沙利文林 A(0.00032-0.01mg/kg);非典型 KOR 激动剂纳呋拉啡(0.0001-0.001mg/kg)和三唑 1.1(0.01-0.32mg/kg);MOR 激动剂奥昔康定(0.0032-0.32mg/kg);作为对照,可卡因(0.032-0.32mg/kg)和氯胺酮(0.32-10mg/kg)。对于时间过程测定,每种 KOR 激动剂或 MOR 激动剂的最大剂量在时间点(10-320min)之间给药。在混合物条件下,奥昔康定(0.1mg/kg)后给予 KOR 激动剂。
典型的 KOR 激动剂产生镇静样和运动障碍作用。纳呋拉啡在大多数结果上与典型的 KOR 激动剂相似,而三唑 1.1 除了在时间过程测定中减少抓挠外,本身没有产生任何作用。在混合物中,所有 KOR 激动剂均减少了奥昔康定引起的搔抓,U50-488H 和纳呋拉啡减少了物种典型的活动,而 U50-488H 增加了休息/睡眠姿势。
与典型的 KOR 激动剂相比,非典型的“偏向”KOR 激动剂产生的副作用谱相对良性(三唑 1.1)或减少(纳呋拉啡)。